Paclitaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paclitaxel albumin bound’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paclitaxel albumin bound overview
Paclitaxel albumin bound (Paclitaxel) is a cyclodecane with anti-neoplastic activity isolated from the bark of the Pacific yew tree, Taxus brevifolia. It is formulated as powder for suspension for intravenous route of administration. Paclitaxel is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy or breast cancer relapse within 6 months of adjuvant chemotherapy.
Paclitaxel albumin bound is also under development for the treatment of advanced gastric cancer, advanced or metastatic biliary tract cancer, epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer. It is administered through intravenous route.
CSPC Pharmaceutical Group overview
CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
For a complete picture of Paclitaxel albumin bound’s drug-specific PTSR and LoA scores, buy the report here.